US5231086A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Continuous administration adenosine to increase myocardial blood flow
Assignee: Item Development AB
•
Filing: 1992-01-14
•
Granted: 1993-07-27
•
Expires: 2012-01-14
Abstract
Abstract This invention is concerned with the use of adenosine as an agent for the treatment of human beings. More particularly, this invention is concerned with the administration of adenosine to human patients by continuous intravenous infusion for, inter alia, control of blood pressure, use as a selective vasodilator, decreasing pulmonary vascular resistance, treating acute pulmonary hypertension in conjunction with idiopathic respiratory distress syndrome, in diagnosing pulmonary hypertension in conjunction with cardiac septum defects, in percutaneous transluminal angioplasty (PTCA), in coronary thrombolysis (CTL) and in radionucleide scintography.
Inventors
- 👤 Alf Sollevi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 01:38
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/7042; A61K31/7052; A61K31/706; A61K31/7064; A61K31/7076; C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/16
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
77 words
A method of dilating the coronary arteries of a human patient in need thereof without inducing a hypotensive state, which comprises administering adenosine into the blood stream of the patient by continuous intravenous infusion at a rate effective to dilate the coronary arteries, while causing systemic arteries to dilate substantially less than the coronary arteries, such rate being from about 30 to 50 μg per kg of body weight per minute when administered in a central vein.
Claim 2
Independent Claim
77 words
A method of dilating the coronary arteries of a human patient in need thereof without inducing a hypotensive state, which comprises administering adenosine into the blood stream of the patient by continuous intravenous infusion at a rate effective to dilate the coronary arteries, while causing systemic arteries to dilate substantially less than the coronary arteries, such rate being from about 30 to 50 μg per kg of body weight per minute when administered in a central vein.
Claim 3
Dependent Claim
47 words
A method according to claim 1 wherein the occlusion of coronary grafts in a human patient who has undergone coronary bypass surgery is inhibited by increasing graft blood flow without increased myocardial work comprising administering adenosine to the blood stream of the patent by continuous intravenous infusion.
Claim 4
Dependent Claim
38 words
A method according to claim 2 comprising administering adenosine at a rate of 0.03 mg to 0.05 mg per kg body weight per minute so as to increase graft flow and obtain preferential vasodilation in the coronary vasculature.
Claim 5
Independent Claim
64 words
A method of dilating the coronary arteries of an anesthetized human patient in need thereof during coronary bypass surgery which comprises administering adenosine into the blood stream of the patient by continuous intravenous infusion so as to cause a preferential coronary vasodilation, the adenosine being administered at dosages from about 30 to 50 μg per kg per minute when administered in a central vein.
Claim 6
Independent Claim
64 words
A method of dilating the coronary arteries of an anesthetized human patient in need thereof during coronary bypass surgery which comprises administering adenosine into the blood stream of the patient by continuous intravenous infusion so as to cause a preferential coronary vasodilation, the adenosine being administered at dosages from about 30 to 50 μg per kg per minute when administered in a central vein.
Claim 7
Dependent Claim
12 words
A method according to claim 1 where the patient is not anesthetized.
Claim 8
Dependent Claim
11 words
A method according to claim 1 where the patient is anesthetized.
Claim 9
Independent Claim
61 words
A method of increasing the myocardial blood flow in a human patient in need thereof which comprises administering adenosine into the blood stream of the patient by continuous intravenous infusion at a rate effective to dilate the coronary arteries, such rate being from about 50 to about 100 μg per kg body weight per minute when administered in a central vein.
Claim 10
Independent Claim
61 words
A method of increasing the myocardial blood flow in a human patient in need thereof which comprises administering adenosine into the blood stream of the patient by continuous intravenous infusion at a rate effective to dilate the coronary arteries, such rate being from about 50 to about 100 μg per kg body weight per minute when administered in a central vein.
References Cited (Backward Citations)
US4673563A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-07-26 | 1997-01-25 | 1997-07-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-07-26 | 2001-01-25 | 2001-07-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-07-26 | 2005-01-25 | 2005-07-27 | $7700.00 | Window Closed / Lapsed |